Guidance, NICE advice and quality standards in development | Guidance

Showing 131 to 140 of 392

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]	Technology appraisal guidance	26 February 2025
Evobrutinib for treating relapsing multiple sclerosis [ID6313]	Technology appraisal guidance	TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance	TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]	Technology appraisal guidance	TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests	Diagnostics guidance	TBC
Falls: assessment and prevention in older people and people 50 and over at higher risk (update)	NICE guideline	26 March 2025
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]	Technology appraisal guidance	TBC
Fertility problems: assessment and treatment	NICE guideline	6 August 2025
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]	Technology appraisal guidance	21 May 2025